CalciMedica is a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels to treatment of inflammatory and autoimmune disorders and organ transplant rejection. CalciMedica is developing treatments for COVID-19 pneumonia and acute pancreatitis.
CRAC channels play a critical role in the transport of calcium, a key messenger molecule, into many cell types. Calcium regulates biological functions and activation of CRAC channels control inflammation, vascular permeability and cell death. CRAC channel inhibitor drug Auxora was developed to treat acute inflammatory conditions such as COVID-19 pneumonia and acute pancreatitis. Drug candidate CM6325 is a potential treatment for chronic conditions such as rheumatoid arthritis and chronic pancreatitis.